Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic…
NCT00003741 · Beth Israel Deaconess Medical Center, Other · Completed
Key facts
| NCT number | NCT00003741 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma |
| Official title | HeFi-1 Antibody Therapy in Ki-1 and Hodgkin's Lymphomas, a Phase I Study |
| Lead sponsor | Beth Israel Deaconess Medical Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | monoclonal antibody HeFi-1 |
| Start date | Feb 1, 1999 |
| Completion | Dec 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: